Abstract 4P
Background
Complications of immediate breast reconstruction caused by chemotherapy or radiotherapy have been debated, but these complications may delay the end of adjuvant treatment and subsequently increase the recurrence. The purpose of this study was to identify risk factors of tissue expander or implant removal and difference of duration from mastectomy to tissue expander or implant removal.
Methods
We conducted a retrospective study of total 11362 breast cancer patients between 2012 and 2017 who were identified in Samsung Medical Center. Eligible patients were total 1091 female breast cancer patients after nipple sparing mastectomy or skin sparing mastectomy with tissue expander or direct implant insertion.
Results
602 (55.2%) patients (group A) have not chemotherapy (CTx), 61 (5.6%) patients (group B) have neoadjuvant CTx and 428 (39.2%) patients (group C) have adjuvant CTx. 897 (82.2%) patients (group D) have not radiotherapy (RTx), 194 (17.8%) patients (group E) have RTx. 1050 (96.2%) patients (group N) have not tissue expander or implant removal and 41 (3.8%) patients (group R) have tissue expander or implant removal. Baseline and pathologic characteristics of patients were not different except N stage between group N and group R. Univariate analysis showed increased pathologic N stage was significantly associated tissue expander or implant removal. (HR = 14.769, 95% CI = 4.338 to 50.284). Tissue expander or implant removal occurred more group B (6.6%) than group A (2.0%) (HR = 3.450, 95% CI = 1.078 to 11.048), more group C (5.8%) than group A (HR = 3.050, 95% CI = 1.515 to 6.141) and more group E (8.8%) than group D (2.7%) (HR = 3.494, 95% CI = 1.839 to 6.639). In multivariate analysis, N stage decreases, tissue expander or implant removal occurred earlier (P < .05). Median time of duration from operation to tissue expander or implant removal was 495 days (range 10-2423 days).
Conclusions
Immediate reconstruction with tissue expander or implant after mastectomy may be a choice of treatment option even in breast cancer patients who will be received chemotherapy or radiotherapy. These results will aid preoperative counselling to patients who are concerned about complication of immediate reconstruction caused by chemotherapy or radiotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract